Arvinas, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Arvinas is a clinical-stage biotechnology company developing PROTAC protein degraders. It has no approved products and has not generated product-sales revenue; reported revenue comes from collaborations and license agreements.
Financial performance and position
- Revenue: $32.5 million, up $6.0 million (23%) from $26.5 million in Q1 2022. The increase primarily reflected higher revenue under the Pfizer ARV-471 collaboration.
- Operating expenses: $120.2 million, up from $84.2 million. Research and development expense rose to $95.3 million from $64.0 million; general and administrative expense rose to $24.9 million from $20.2 million.
- Loss: Operating loss was $87.7 million versus $57.7 million. Net loss was $81.9 million, or $1.54 per share, versus $63.4 million, or $1.20 per share. Higher interest income and a tax benefit partly offset increased operating costs.
- Cash flow: Operating cash use was $91.2 million, compared with $57.1 million in Q1 2022. Investing activities provided $138.6 million, primarily reflecting marketable-security maturities and sales exceeding purchases; financing activities provided $1.5 million. Cash, cash equivalents and restricted cash increased $48.9 million to $135.7 million.
- Liquidity and debt: Cash, cash equivalents, restricted cash and marketable securities totaled approximately $1.1 billion at March 31, 2023, including $993.3 million in marketable securities. Total debt was $1.0 million. Management expects existing resources to fund planned operating expenses and capital needs into 2026, subject to assumptions and potential earlier use of funds.
- Other metrics: Stock-based compensation was $19.9 million, versus $16.6 million. Total stockholders’ equity was $511.0 million, down from $564.9 million at year-end 2022. The filing does not provide a clear gross-margin measure.
Material changes and operating developments
- R&D expense increased $31.3 million, driven by expanded platform and exploratory research, higher spending on the androgen-receptor and estrogen-receptor programs, and personnel and clinical/manufacturing costs.
- Revenue included a $15.9 million increase from the ARV-471/Pfizer collaboration, partly offset by $8.2 million of lower revenue associated with extended recognition periods under the Pfizer research and Bayer collaborations, and a $1.2 million decrease in previously constrained Oerth Bio revenue.
- Q1 2023 included an $8.2 million cumulative catch-up adjustment from contract modifications relating to performance obligations satisfied in prior periods. Deferred revenue was $593.8 million at quarter-end; the company expects to recognize it over future periods.
- The company corrected an immaterial prior-period Oerth Bio accounting error in the Q1 2022 comparative figures: revenue and operating loss each increased by $2.3 million, with no impact on net loss or loss per share.
Outlook, risks and contingencies
- Management expects operating losses and R&D spending to rise as clinical and research programs advance. The company expects no product-sales revenue in the foreseeable future and says additional financing will be needed; potential collaboration payments are not committed funding.
- Key stated 2023 plans included completing VERITAC-2 enrollment in the second half of 2024; starting the vepdegestrant first-line Phase 3 safety lead-in and additional combination-trial arms in the second half of 2023; initiating a global bavdegalutamide Phase 3 trial in the second half of 2023; and reporting ARV-766 dose-escalation data in Q2 2023. These are forward-looking plans, not assurances.
- For vepdegestrant with palbociclib, preliminary Phase 1b results showed a 60.7% clinical benefit rate among 28 evaluable patients. Increased palbociclib exposure and a higher incidence of grade 3/4 neutropenia were observed; the filing describes management through monitoring and dose modification.
- Clinical, regulatory, manufacturing, commercialization, financing, intellectual-property and collaboration risks could delay or prevent product development or approval. Management cautions that its runway estimate depends on assumptions and capital could be used sooner than expected.
- The company accrued $7.0 million, primarily for an early-stage contract dispute. The possible loss range could not be estimated; the means of resolution were unknown. It reported no material legal proceedings.
- A new laboratory and office lease is expected to be occupied in 2025; once occupied, annual base rent is expected to range from $7.7 million to $8.8 million over a ten-year term. Connecticut assistance agreements also require the company to remain in the state through specified dates and carry repayment penalties for noncompliance.
Important facts for investors to verify
- Whether clinical-trial timelines, enrollment, safety findings and planned data disclosures have progressed as expected.
- Whether collaboration revenue, deferred-revenue recognition and cost sharing—particularly with Pfizer—remain consistent with the filing’s assumptions.
- Cash and marketable-security balances, operating cash burn, and whether the stated runway into 2026 remains supportable.
- Developments and potential financial exposure relating to the $7.0 million contract-dispute accrual.
- Whether additional financing, collaboration payments or future milestone receipts are needed to fund operations, and the potential dilution or rights granted to obtain funding.